Looking for an ivonescimab encore
What similarly acting projects are still unpartnered?
ESMO 2024 – Regeneron's fianlimab do-over
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ESMO 2024 – Keytruda/Lenvima leap... up to a point
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
ESMO 2024 – Incyte tries again in anal cancer
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
ESMO 2024 preview – Summit could take on Merck in breast cancer
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
